Bortezomib induces heme oxygenase-1 expression in multiple myeloma

Cell Cycle

Volumn 11, Issue 12, 2012, Pages 2248-2252

  Barrera, Lawrence N ^a   Rushworth, Stuart A ^a   Bowles, Kristian M ^b   MacEwan, David J ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bortezomib; Heme oxygenase 1; Multiple myeloma; Nrf2

Indexed keywords

BORTEZOMIB; HEME OXYGENASE 1; LENALIDOMIDE;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL PROTECTION; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84862898009     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20343     Document Type: Review

References (30)

1. Harousseau JL, Dreyling M; ESMO Guidelines Working Group. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow- up. Ann Oncol 2008; 19:55-7; PMID:18456769; http://dx.doi.org/10.1093/annonc/mdn088.
2. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119:2764-7; PMID:22323483; http://dx.doi.org/10.1182/blood-2011-08-373514.
3. Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, et al. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol 2012; 88:446-9; PMID:22300348; http://dx.doi.org/10.1111/j.1600- 0609.2012.01765.x.
4. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003; 101:4098-104; PMID:12531810; http://dx.doi.org/10.1182/blood-2002-08-2512.
5. Rushworth SA, Bowles KM, MacEwan DJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res 2011; 71:1999-2009; PMID:21212410; http://dx.doi.org/10.1158/0008-5472.CAN-10- 3018.
6. Schäfer M, Dütsch S, auf dem Keller U, Werner S. Nrf2: a central regulator of UV protection in the epidermis. Cell Cycle 2010; 9:2917-8; PMID:20699662; http://dx.doi.org/10.4161/cc.9.15.12701.
7. Alam J, Stewart D, Touchard C, Boinapally S, Choi AMK, Cook JL. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 1999; 274:26071- 8; PMID:10473555; http://dx.doi.org/10.1074/ jbc.274.37.26071.
8. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275:16023- 9; PMID:10821856; http://dx.doi.org/10.1074/jbc.275.21.16023.
9. Villeneuve NF, Sun Z, Chen W, Zhang DD. Nrf2 and p21 regulate the fine balance between life and death by controlling ROS levels. Cell Cycle 2009; 8:3255-6; PMID:19806015; http://dx.doi.org/10.4161/cc.8.20.9565.
10. Sun J, Hoshino H, Takaku K, Nakajima O, Muto A, Suzuki H, et al. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J 2002; 21:5216-24; PMID:12356737; http://dx.doi.org/10.1093/emboj/cdf516.
11. Dhakshinamoorthy S, Jain AK, Bloom DA, Jaiswal AK. Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants. J Biol Chem 2005; 280:16891-900; PMID:15734732; http://dx.doi.org/10.1074/jbc.M500166200.
12. Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. Identification of binding sites for transcription factors NFκB and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci USA 1994; 91:5987- 91; PMID:8016102; http://dx.doi.org/10.1073/pnas.91.13.5987.
13. Rushworth SA, Bowles KM, Raninga P, MacEwan DJNF. NFkappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase- 1 induction. Cancer Res 2010; 70:2973-83; PMID:20332229; http://dx.doi.org/10. 1158/0008-5472.CAN-09-3407.
14. Kirino Y, Takeno M, Murakami S, Kobayashi M, Kobayashi H, Miura K, et al. Tumor necrosis factor alpha acceleration of inflammatory responses by downregulating heme oxygenase 1 in human peripheral monocytes. Arthritis Rheum 2007; 56:464- 75; PMID:17265482; http://dx.doi.org/10.1002/art.22370.
15. Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003; 6:15-24; PMID:14517400; http://dx.doi.org/10.1023/A: 1025803600840.
16. Rushworth SA, Zaitseva L, Langa S, Bowles KM, MacEwan DJ. FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget 2010; 1:359-66; PMID:21307400.
17. Heasman SA, Zaitseva L, Bowles KM, Rushworth SA, MacEwan DJ. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget 2011; 2:658-68; PMID:21911919.
18. Mayerhofer M, Florian S, Krauth MT, Aichberger KJ, Bilban M, Marculescu R, et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res 2004; 64:3148-54; PMID:15126353; http://dx.doi.org/10.1158/0008-5472.CAN-03-1200.
19. Rakshit S, Bagchi J, Mandal L, Paul K, Ganguly D, Bhattacharjee S, et al. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide. Apoptosis 2009; 14:298-308; PMID:19153832; http://dx.doi.org/10.1007/s10495-008-0305-7.
20. Mayerhofer M, Gleixner KV, Mayerhofer J, Hoermann G, Jaeger E, Aichberger KJ, et al. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 2008; 111:2200- 10; PMID:18024796; http://dx.doi.org/10.1182/blood-2006-11-055723.
21. Rushworth SA, MacEwan DJ. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 2008; 111:3793-801; PMID:18202225; http://dx.doi.org/10.1182/blood-2007-07-104042.
22. Miyazaki T, Kirino Y, Takeno M, Samukawa S, Hama M, Tanaka M, et al. Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1. Cancer Sci 2010; 101:1409-16; PMID:20345481; http://dx.doi.org/10.1111/j.1349-7006.2010.01550.x.
23. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009; 34:176-88; PMID:19321346; http://dx.doi.org/10.1016/j.tibs.2008.12.008.
24. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008; 373:151- 4; PMID:18555005; http://dx.doi.org/10.1016/j.bbrc. 2008.06.004.
25. Herrmann H, Kneidinger M, Cerny-Reiterer S, Rülicke T, Willmann M, Gleixner KV, et al. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34(+)/ CD38(+) and CD34(+)/CD38(-) AML progenitor cells. Curr Cancer Drug Targets 2012; 12:51-63; PMID:22165967; http://dx.doi.org/10.2174/156800912798888992.
26. Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CCN, et al. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010; 107:7479-84; PMID:20368435; http://dx.doi. org/10.1073/pnas.1002890107.
27. Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, et al. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. J Pathol 2011; 224:90-100; PMID:21381033; http:// dx.doi.org/10.1002/path.2855.
28. Singh MM, Irwin ME, Gao Y, Ban K, Shi P, Arlinghaus RB, et al. Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia. Cancer 2011; In press; PMID:22139798; http://dx.doi.org/10.1002/cncr. 26621.
29. Zhou P, Kalakonda N, Comenzo RL. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol 2005; 128:636-44; PMID:15725085; http://dx.doi.org/10.1111/j.1365-2141.2005.05369.x.
30. Bancos S, Baglole CJ, Rahman I, Phipps RP. Induction of heme oxygenase-1 in normal and malignant B lymphocytes by 15-deoxy-Δ(12,14)-prostaglandin J(2) requires Nrf2. Cell Immunol 2010; 262:18-27; PMID:20064636; http://dx.doi. org/10.1016/j.cellimm.2009.12.003.